Europe and the United States from 2002 began to carry out the catheter aortic valve treatment technology, the technology is known as the "fourth revolution" of the field of cardiovascular intervention. Catheter aortic valve therapy compared with standard therapy, patients with one-year risk of death was reduced by 46%. Have been over 50,000 cases of patients around the world benefit from this treatment.
Previously, aortic catheterization, only Medtronic and Edwards produced products more expensive. The Hangzhou of Qiming Medical Company production of domestic aortic valvular project of the national "863" units of industrialization, the the enterprise once high rated National SME Innovation Fund support. Valve of the R & D process, the enterprise and Fu Wai Hospital, experts conducted a total of 60 times to adjust and improve.
According to the National Cardiovascular Center Runlin Academician, compared with the similar products in Europe and the United States, the domestic valvular design more reasonable. It is a kind of self-expansion biofilm lobes, the first clinical application of recyclable transcatheter valve system.
If you have any questions, please feel free to contact us.
没有评论:
发表评论